How much do paid clinical trials in Kalamazoo pay?

Compensation varies by study length, procedures and overnight stays. Industry surveys report typical payments from $75 to $4,500 per completed study, with simple observational studies at the low end and multi-week inpatient Phase 1 studies at the high end. Each listing's study team will confirm the exact amount before you enroll.

Are clinical trials in Kalamazoo safe?

Every trial on this page is registered on ClinicalTrials.gov, the official NIH registry, and is overseen by an Institutional Review Board (IRB). Before joining you receive an informed consent document detailing procedures, risks and compensation. Participation is voluntary and you can withdraw at any time.

How do I join a study in Kalamazoo, MI?

Pick a study that matches your profile, contact the research site (or apply through the study links on this page), pass a phone pre-screen, then attend an in-person screening visit. If you qualify, you review and sign the informed consent and the study begins. The process typically takes 1-3 weeks.

What is the difference between a research center and a hospital study in Kalamazoo?

Dedicated research centers (listed on this page with their Google ratings) run studies as their core business — often healthy-volunteer and vaccine studies with structured compensation. Hospital and university studies tend to focus on patients with specific conditions. Both types are registered and IRB-supervised.

Can I be in more than one clinical trial at a time?

Generally no — most studies exclude participants currently enrolled in another trial, and paid Phase 1 studies enforce a washout period (often 30 days or more) between studies. Frequent healthy volunteers in Kalamazoo typically complete one or two studies per year.

Paid Clinical Trials Kalamazoo, MI — 109 Studies Recruiting (Jul 2026)

Optimizing Reperfusion to Improve Outcomes and Neurologic Function

Acute Ischemic Stroke Phase 2, Phase 3 Interventional 740 participants sought

Corxel Investigational Site — Kalamazoo, Michigan (1.2 mi) · Sponsor: Corxel Pharmaceuticals

See eligibility & contact on ClinicalTrials.gov (NCT06990867)

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

Multiple conditions Phase 2 Interventional 150 participants sought

Bronson Methodist Hospital — Kalamazoo, Michigan (1.2 mi) · Sponsor: National Cancer Institute (NCI)

See eligibility & contact on ClinicalTrials.gov (NCT05136196)

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

Ganglioneuroblastoma, Nodular, Neuroblastoma Phase 3 Interventional 478 participants sought

Bronson Methodist Hospital — Kalamazoo, Michigan (1.2 mi) · Sponsor: National Cancer Institute (NCI)

See eligibility & contact on ClinicalTrials.gov (NCT06172296)

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma Phase 3 Interventional 1,450 participants sought

Bronson Methodist Hospital — Kalamazoo, Michigan (1.2 mi) · Sponsor: ECOG-ACRIN Cancer Research Group

See eligibility & contact on ClinicalTrials.gov (NCT04566328)

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

Classic Follicular Lymphoma, Follicular Lymphoma With Unusual Cytological Features Phase 3 Interventional 600 participants sought

Bronson Methodist Hospital — Kalamazoo, Michigan (1.2 mi) · Sponsor: National Cancer Institute (NCI)

See eligibility & contact on ClinicalTrials.gov (NCT06337318)

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma Phase 3 Interventional 255 participants sought

Bronson Methodist Hospital — Kalamazoo, Michigan (1.2 mi) · Sponsor: National Cancer Institute (NCI)

See eligibility & contact on ClinicalTrials.gov (NCT07198074)

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7 Phase 2, Phase 3 Interventional 613 participants sought

West Michigan Cancer Center — Kalamazoo, Michigan (1.2 mi) · Sponsor: National Cancer Institute (NCI)

See eligibility & contact on ClinicalTrials.gov (NCT01810913)

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

Ovarian Carcinoma N/A Interventional 1,956 participants sought

Bronson Methodist Hospital — Kalamazoo, Michigan (1.2 mi) · Sponsor: NRG Oncology

See eligibility & contact on ClinicalTrials.gov (NCT04251052)

Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma

Metastatic Malignant Neoplasm in the Lung, Metastatic Osteosarcoma Phase 3 Interventional 62 participants sought

Bronson Methodist Hospital — Kalamazoo, Michigan (1.2 mi) · Sponsor: Children's Oncology Group

See eligibility & contact on ClinicalTrials.gov (NCT05235165)

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

Breast Carcinoma, Colorectal Carcinoma N/A Observational 2,000 participants sought

West Michigan Cancer Center — Kalamazoo, Michigan (1.2 mi) · Sponsor: Wake Forest University Health Sciences

See eligibility & contact on ClinicalTrials.gov (NCT06418204)

Tailoring a Home Supervision Intervention for Latinx Caregivers

Healthy N/A Interventional 100 participants sought

Western Michigan University — Kalamazoo, Michigan (1.2 mi) · Sponsor: Western Michigan University

See eligibility & contact on ClinicalTrials.gov (NCT07203612)

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia Phase 3 Interventional 556 participants sought

Bronson Methodist Hospital — Kalamazoo, Michigan (1.2 mi) · Sponsor: Children's Oncology Group

See eligibility & contact on ClinicalTrials.gov (NCT07022678)

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

Ovarian Neoplasms, Fallopian Tube Neoplasms Phase 3 Interventional 1,630 participants sought

West Michigan Cancer Center — Kalamazoo, Michigan (1.2 mi) · Sponsor: Eli Lilly and Company

See eligibility & contact on ClinicalTrials.gov (NCT07213804)

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

Stage I Breast Cancer Phase 3 Interventional 1,670 participants sought

Bronson Methodist Hospital — Kalamazoo, Michigan (1.2 mi) · Sponsor: NRG Oncology

See eligibility & contact on ClinicalTrials.gov (NCT04852887)

Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors

Breast Cancer, Cognitive Impairments N/A Interventional 386 participants sought

Bronson Methodist Hospital — Kalamazoo, Michigan (1.2 mi) · Sponsor: NRG Oncology

See eligibility & contact on ClinicalTrials.gov (NCT05896189)

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Intracranial Meningioma, Recurrent Meningioma Phase 2 Interventional 124 participants sought

Bronson Methodist Hospital — Kalamazoo, Michigan (1.2 mi) · Sponsor: Alliance for Clinical Trials in Oncology

See eligibility & contact on ClinicalTrials.gov (NCT02523014)

Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS

Acute Coronary Syndrome Phase 3 Interventional 2,000 participants sought

Research Site — Kalamazoo, Michigan (1.2 mi) · Sponsor: DalCor Pharmaceuticals

See eligibility & contact on ClinicalTrials.gov (NCT05918861)

Transcutaneous Electrical Stimulation and Controlled Heat in People With and Without Diabetes

Diabetes, Heat N/A Interventional 20 participants sought

Western Michigan University — Kalamazoo, Michigan (1.2 mi) · Sponsor: Western Michigan University

See eligibility & contact on ClinicalTrials.gov (NCT07063524)

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

Extensive Stage Lung Small Cell Carcinoma Phase 2, Phase 3 Interventional 138 participants sought

Bronson Methodist Hospital — Kalamazoo, Michigan (1.2 mi) · Sponsor: National Cancer Institute (NCI)

See eligibility & contact on ClinicalTrials.gov (NCT04402788)

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

Anaplastic Kidney Wilms Tumor, Recurrent Kidney Wilms Tumor Phase 2 Interventional 256 participants sought

Bronson Methodist Hospital — Kalamazoo, Michigan (1.2 mi) · Sponsor: Children's Oncology Group

See eligibility & contact on ClinicalTrials.gov (NCT04322318)

An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

Schizophrenia Phase 3 Interventional 280 participants sought

Local Institution - 162 — Kalamazoo, Michigan (1.2 mi) · Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company

See eligibility & contact on ClinicalTrials.gov (NCT05304767)

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8 Phase 3 Interventional 3,680 participants sought

Bronson Methodist Hospital — Kalamazoo, Michigan (1.2 mi) · Sponsor: National Cancer Institute (NCI)

See eligibility & contact on ClinicalTrials.gov (NCT06058377)

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma Phase 3 Interventional 1,210 participants sought

Bronson Methodist Hospital — Kalamazoo, Michigan (1.2 mi) · Sponsor: National Cancer Institute (NCI)

See eligibility & contact on ClinicalTrials.gov (NCT04267848)

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 Phase 3 Interventional 1,524 participants sought

Bronson Methodist Hospital — Kalamazoo, Michigan (1.2 mi) · Sponsor: Alliance for Clinical Trials in Oncology

See eligibility & contact on ClinicalTrials.gov (NCT06876714)

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

Previously Treated Non-Small Cell Lung Cancer Phase 2, Phase 3 Interventional 10,000 participants sought

Bronson Methodist Hospital — Kalamazoo, Michigan (1.2 mi) · Sponsor: SWOG Cancer Research Network

See eligibility & contact on ClinicalTrials.gov (NCT03851445)

Paid Clinical Trials in Kalamazoo, MI

Studies recruiting near Kalamazoo right now

Optimizing Reperfusion to Improve Outcomes and Neurologic Function

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

Tailoring a Home Supervision Intervention for Latinx Caregivers

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS

Transcutaneous Electrical Stimulation and Controlled Heat in People With and Without Diabetes

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

Top-rated research centers in Kalamazoo

Center for Clinical Research at WMed

Center For Clinical Research Solutions

West Michigan Cancer Center

West Michigan Clinical Research Center

WMed Innovation Center

Lighthouse Autism Center - Kalamazoo

Kalamazoo Autism Center

Clinical trials in Kalamazoo: what's recruiting

How to enroll in a paid study in Kalamazoo

Frequently asked questions

Paid clinical trials near Kalamazoo

More of MI

New paid studies open every week